JPMorgan Chase & Co. Sells 112,649 Shares of STAAR Surgical Company $STAA

JPMorgan Chase & Co. trimmed its position in shares of STAAR Surgical Company (NASDAQ:STAA – Free Report) by 73.4% during the 3rd quarter, Holdings Channel reports. The firm owned 40,722 shares of the medical instruments supplier’s stock after selling 112,649 shares during the period. JPMorgan Chase & Co.’s holdings in STAAR Surgical were worth $1,094,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of the company. Broadwood Capital Inc. raised its position in shares of STAAR Surgical by 8.5% during the 2nd quarter. Broadwood Capital Inc. now owns 13,519,491 shares of the medical instruments supplier’s stock valued at $226,857,000 after purchasing an additional 1,064,227 shares during the period. Soleus Capital Management L.P. raised its position in shares of STAAR Surgical by 16.5% during the 2nd quarter. Soleus Capital Management L.P. now owns 2,984,733 shares of the medical instruments supplier’s stock valued at $50,084,000 after purchasing an additional 421,840 shares during the period. Yunqi Capital Ltd raised its position in shares of STAAR Surgical by 3.7% during the 3rd quarter. Yunqi Capital Ltd now owns 2,500,061 shares of the medical instruments supplier’s stock valued at $67,177,000 after purchasing an additional 88,773 shares during the period. Balyasny Asset Management L.P. bought a new stake in shares of STAAR Surgical during the 3rd quarter valued at $48,729,000. Finally, Magnetar Financial LLC bought a new stake in shares of STAAR Surgical during the 3rd quarter valued at $32,361,000. 96.70% of the stock is currently owned by institutional investors.

Insider Transactions at STAAR Surgical

In related news, Director Broadwood Partners, L.P. purchased 316,017 shares of STAAR Surgical stock in a transaction on Friday, March 13th. The shares were bought at an average cost of $18.61 per share, for a total transaction of $5,881,076.37. Following the acquisition, the director owned 16,123,842 shares in the company, valued at approximately $300,064,699.62. The trade was a 2.00% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In the last 90 days, insiders have acquired 670,213 shares of company stock valued at $12,266,249. Insiders own 0.59% of the company’s stock.

Analysts Set New Price Targets

Several analysts have recently commented on the stock. Stifel Nicolaus decreased their price objective on shares of STAAR Surgical from $19.00 to $18.00 and set a “hold” rating on the stock in a research report on Wednesday, March 4th. Jefferies Financial Group decreased their price objective on shares of STAAR Surgical from $28.00 to $21.50 and set a “buy” rating on the stock in a research report on Wednesday, January 28th. Wedbush raised their price objective on shares of STAAR Surgical from $21.00 to $26.00 and gave the company a “neutral” rating in a research report on Thursday. Needham & Company LLC reiterated a “hold” rating on shares of STAAR Surgical in a report on Tuesday, January 6th. Finally, Wall Street Zen upgraded shares of STAAR Surgical to a “hold” rating in a report on Saturday. Two research analysts have rated the stock with a Buy rating, seven have given a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, STAAR Surgical presently has an average rating of “Hold” and a consensus price target of $19.93.

Read Our Latest Report on STAAR Surgical

STAAR Surgical News Roundup

Here are the key news stories impacting STAAR Surgical this week:

• Positive Sentiment: Preliminary Q1 net sales came in well ahead of expectations (sales more than doubled vs. year-ago), signaling stronger demand and improving revenue momentum for STAA. Preliminary Net Sales
• Positive Sentiment: STAAR issued a bullish sales outlook (coverage cites a ~$90M sales outlook), which investors interpreted as “blowout” guidance versus prior expectations and lifted sentiment. Blowout Sales Outlook
• Positive Sentiment: Canaccord Genuity upgraded STAA from Hold to Buy and raised its price target to $27, adding credible analyst support to the rally. Canaccord Upgrade
• Neutral Sentiment: Wedbush raised its price target to $26 but maintained a Neutral rating, a modestly constructive move that stops short of a full buy call. Wedbush Note
• Neutral Sentiment: Broad market coverage (Bloomberg, Seeking Alpha, MarketWatch and others) increased visibility and trading volume; media attention can amplify intraday moves but doesn’t change fundamentals by itself. Bloomberg Coverage
• Negative Sentiment: STAAR still has a recent history of negative EPS and missed consensus in its March quarter report; profitability remains a concern and analysts still forecast negative full‑year EPS. Profitability Background
• Neutral Sentiment: The company reportedly updated Q1 guidance in a brief release but the published entry lacked a clear EPS figure; investors should watch the formal filing/earnings release for details. Guidance Note

STAAR Surgical Stock Performance

Shares of NASDAQ STAA opened at $26.44 on Friday. The company has a market cap of $1.31 billion, a P/E ratio of -16.22 and a beta of 1.04. The firm’s fifty day moving average is $18.71 and its two-hundred day moving average is $22.63. STAAR Surgical Company has a 52-week low of $15.42 and a 52-week high of $30.81.

STAAR Surgical (NASDAQ:STAA – Get Free Report) last announced its quarterly earnings results on Tuesday, March 3rd. The medical instruments supplier reported ($0.37) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.14 by ($0.51). The company had revenue of $57.80 million during the quarter, compared to the consensus estimate of $75.54 million. STAAR Surgical had a negative net margin of 33.60% and a negative return on equity of 10.03%. The company’s quarterly revenue was up 18.0% on a year-over-year basis. As a group, analysts forecast that STAAR Surgical Company will post -1.14 EPS for the current fiscal year.

STAAR Surgical Company Profile

(Free Report)

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia. It markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as products are primarily used by ophthalmologists.

Recommended Stories

• Five stocks we like better than STAAR Surgical

Want to see what other hedge funds are holding STAA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for STAAR Surgical Company (NASDAQ:STAA – Free Report).